Expression of the CD30 antigen in non‐lymphoid tissues and cells

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Pathology

• Publication date

  2000-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0PMID 10727988
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Germ cell tumors of the mediastinum and testis: a comparative immunohistochemical study of 120 cases.

  1999cited by this paper
• A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours

  1998cited by this paper
• Histological Typing of Testis Tumours

  1998cited by this paper
• CD30 expression in seminoma.

  1996cited by this paper
• Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

  1996cited by this paper
• CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.

  1995cited by this paper
• Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues

  1995cited by this paper
• CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

  1995cited by this paper
• Diffuse embryoma of the testis. An immunohistochemical study of two cases.

  1994cited by this paper
• High expression of the CD30 molecule in human decidual cells.

  1994cited by this paper
• Ber-H2 expression in testicular germ cell tumors.

  1994cited by this paper
• Tumor necrosis factor receptor superfamily members and their ligands.

  1994cited by this paper
• Expression of CD 30 and nerve growth factor‐receptor in neoplastic and reactive vascular lesions: an immunohistochemical study

  1993cited by this paper
• Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.

  1992cited by this paper
• Ber‐H2 staining of lipoblasts

  1991cited by this paper
• Antigenic profile of mammary fibroadenoma and cystosarcoma phyllodes. A study using antibodies to estrogen- and progesterone receptors and to a panel of cell surface molecules.

  1990cited by this paper
• The diagnostic significance of the CD30 (Ki‐1) antigen

  1990cited by this paper
• Expression of Ki‐1 antigen (CD30) in mesenchymal tumors

  1990cited by this paper
• Human macrophages can express the Hodgkin's cell-associated antigen Ki-1 (CD30).

  1989influential reference
• BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope.

  1989cited by this paper
• In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: Evidence for predominant expression in nonparenchymal liver cells

  1989cited by this paper
• Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma.

  1988cited by this paper
• Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines.

  1987influential reference
• The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

  1985cited by this paper
• Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

  1984cited by this paper
• Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

  1982cited by this paper
• Two neoplastic cell lines with unique features derived from Hodgkin's disease

  1980cited by this paper
• Atlas of Tumor Pathology

  1954cited by this paper

• CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

  2025cites this paper
• Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia/lymphoma

  2025cites this paper
• Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review

  2024cites this paper
• Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome.

  2024cites this paper
• Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions.

  2023cites this paper
• Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study

  2023cites this paper
• Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity

  2023cites this paper
• The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

  2022cites this paper
• CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice

  2022cites this paper
• Hodgkinoid histiocytosis: an atypical nodal CD30 and S100‐positive histiocytosis with eosinophilia

  2022cites this paper
• Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting.

  2022cites this paper
• The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas

  2021cites this paper
• Brentuximab

  2020cites this paper
• Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets

  2020cites this paper
• Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets

  2020cites this paper
• Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

  2020cites this paper
• Circulating CD30 + CD4 + T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption

  2020cites this paper
• Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1

  2020cites this paper
• Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review

  2020cites this paper
• Current Development of Monoclonal Antibodies in Cancer Therapy.

  2020cites this paper
• Circulating CD30+ CD4+ T Cells Increase Prior to HIV Rebound Following Analytical Antiretroviral Treatment Interruption.

  2020cites this paper
• Brentuximab vedotin in T-cell lymphoma

  2019cites this paper
• Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis

  2019cites this paper
• Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics

  2019influential citation
• The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.

  2019cites this paper
• A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

  2019cites this paper
• Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

  2018cites this paper
• The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)

  2018cites this paper
• Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30

  2018cites this paper
• Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas

  2018cites this paper
• Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

  2017influential citation
• Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

  2017cites this paper
• Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.

  2017cites this paper
• Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?

  2017cites this paper
• CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia

  2017cites this paper
• potent and selective antitumor activity

  2017cites this paper
• Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

  2017cites this paper
• Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

  2017cites this paper
• The management of hodgkin lymphomas in pregnancies

  2017cites this paper
• CD30: receptor, marker, target

  2016cites this paper
• Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody

  2016cites this paper
• Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease.

  2015cites this paper
• TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation

  2015cites this paper
• CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma

  2015cites this paper
• The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma

  2015cites this paper
• The Standard of Care in Relapsed Refractory CD30+ Lymphoma

  2014cites this paper
• Detection and characterization of circulating tumor cells in patients with testicular germ cell tumors and prostate cancer

  2014cites this paper
• CD30 as a Therapeutic Target for Lymphoma

  2014cites this paper
• CD30 in Lymphoma: Its Role in Biology, Diagnostic Testing, and Targeted Therapy

  2014cites this paper
• Role of CD30 Targeting in Malignant Lymphoma

  2014cites this paper
• Microsatellite Instability within the CD30 Gene Promoter Distinguishes between Normal and Neoplastic Cells in Lymphoma

  2014cites this paper
• CD30 expression in lymphoid neoplasms: from diagnostic marker to target of therapy

  2014cites this paper
• Lymphomatoid papulosis in children: a series of 25 cases

  2014cites this paper
• CD30 Expression in Malignant Vascular Tumors and Its Diagnostic and Clinical Implications: A Study of 146 Cases

  2014cites this paper
• CD30 in systemic mastocytosis.

  2014cites this paper
• A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord–stromal tumours

  2013cites this paper
• Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin

  2013cites this paper
• CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

  2013cites this paper
• Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.

  2013cites this paper
• Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies

  2013cites this paper
• Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype

  2013cites this paper
• Identificaçao de marcador embrionário em tumor de córtex adrenal de crianças

  2013cites this paper
• Time to look for CD30 expression in diffuse large B-cell lymphomas, along the way to immunotherapy

  2013cites this paper
• Multi-Lineage Interrogation of the Performance Characteristics of a Split-Signal Fluorescence In Situ Hybridization Probe for Anaplastic Lymphoma Kinase Gene Rearrangements

  2012cites this paper
• Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

  2012cites this paper
• Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.

  2012cites this paper
• Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas

  2012cites this paper
• Genetic and Epigenetic Instability of Human Pluripotent Stem Cells

  2011cites this paper
• Expansion of human embryonic stem cells: a comparative study

  2011cites this paper
• CD30-targeted antibody therapy

  2011cites this paper
• Nonlymphoid Lesions of the Lymph Nodes

  2011cites this paper
• Classical Hodgkin's Lymphoma

  2011cites this paper
• Ascorbate Promotes Epigenetic Activation of CD30 in Human Embryonic Stem Cells

  2010cites this paper
• Immunohistochemical Evaluation of CON6D/B5: A New CD30 Monoclonal Antibody

  2010cites this paper
• Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.

  2010cites this paper
• Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo.

  2009cites this paper
• Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions.

  2009cites this paper
• Therapeutic targets of the TNF superfamily

  2009cites this paper
• Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.

  2009cites this paper
• Myocardial Adenomatoid Tumor in Eight Cattle: Evidence for Mesothelial Origin of Bovine Myocardial Epithelial Inclusions

  2009cites this paper
• Embryonic vaccines against cancer: an early history.

  2009cites this paper
• Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas

  2008cites this paper
• Human Embryonic Stem Cells Passaged Using Enzymatic Methods Retain a Normal Karyotype and Express CD30

  2008cites this paper
• Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.

  2008cites this paper
• Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney).

  2008cites this paper
• CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis.

  2008cites this paper
• Embryonic Stem Cell Transcription Factor Signatures in the Diagnosis of Primary and Metastatic Germ Cell Tumors

  2007cites this paper
• Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

  2007cites this paper
• Anaplastic Large-Cell Lymphoma

  2007cites this paper
• D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30

  2007cites this paper
• Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs?

  2007cites this paper
• CD30 (Ber-H2) expression by thymocytes and thymic epithelial cells during the late first and second trimester of gestation: an immunohistochemical and in situ hybridization (ISH) study.

  2007cites this paper
• OCT4: A Sensitive and Specific Immunohistochemical Marker for Metastatic Germ Cell Tumors

  2006cites this paper
• Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.

  2006cites this paper
• CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators

  2006cites this paper
• OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy.

  2006cites this paper
• Immunoplacental therapy, a potential multi-epitope cancer vaccine.

  2006cites this paper
• SGN-30 (Seattle genetics).

  2006cites this paper
• CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells

  2006cites this paper
• Nasopharyngeal carcinoma mimicking large‐cell anaplastic lymphoma

  2005cites this paper